Asociación entre la periodontitis crónica y la respuesta inmunológica TH2

The periodontal disease affects a great part of the world’s population. This disease is a result of the interaction of the host with the microorganisms in the biofilm; therefore the type of immunological reaction will determine the grade of the disease. The Th1/ Th2 balance, was determined by immunohistochemistry (using interferon gamma and interleukin-13) in histological sections of biopsies of the gum of patients previously diagnosed clinical and histologically. The result was a prevalence of Th1 in health and a balance Th1/Th2 in gingivitis with a trend toward Th2 in periodontitis.La enfermedad periodontal afecta una gran parte de la población mundial. Dicha enfermedad es resultado de la interacción del hospedero con los microorganismos de la biopelícula, por lo cual, el tipo de respuesta inmunológica que prevalezca determinará el grado de la enfermedad. Se determinó el balance TH1/ TH2 por la determinación inmunohistoquímica de interferón gamma e interleucina-13 en cortes histológicos de biopsias de encía de sujetos diagnosticados clínicamente e histológicamente, encontrando un predominio de la respuesta Th1 en salud, que se va perdiendo, con equilibrio Th1/Th2 en gingivitis y finalmente, un predominio Th2 en la periodontitis

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN